Bruno P.
- Country
- Italy
- Department
- Oncologia
Research Overview
- Phase II Open-Label Evaluation of Sacituzumab Govitecan in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Randomized Double-Blind Study of Talazoparib and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase 3 Multinational Randomized Study of Sasanlimab with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
Data & Insights
Has run more than one trial at 167 of 364 partner sites.
Specializations
Urological Oncology
This investigator specializes in treating various forms of urological cancers, with particular emphasis on urothelial carcinoma and bladder cancer. Their research includes innovative approaches to non-muscle invasive bladder cancer treatment and advanced therapeutic strategies for locally advanced and metastatic disease.
- Advanced Urothelial Cancer Treatment
- Bladder Cancer Immunotherapy
- Novel Therapeutic Combinations
Prostate Cancer Research
The investigator focuses on developing treatments for various stages of prostate cancer, including both metastatic castration-resistant and castration-sensitive prostate cancer. Their work encompasses innovative therapeutic approaches using hormone therapy combinations and targeted treatments.
- Hormone Therapy Optimization
- Novel Drug Combinations
- Treatment of Advanced Disease
Kidney Cancer Treatment
This specialist investigates treatments for renal cell carcinoma, with particular attention to metastatic renal cell carcinoma and oligometastatic disease. Their research includes evaluation of novel therapeutic combinations and targeted approaches for various stages of kidney cancer.
- Immunotherapy Applications
- Targeted Therapy Development
- Management of Metastatic Disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.